Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities (Q36416211)

14 August 2017

1 reference

title

Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities (English)

1 reference

14 August 2017

0 references

1 reference

L Monnier

1

1 reference

PubMed ID

16523182

14 August 2017

C Colette

series ordinal

2

1 reference

14 August 2017

1 February 2006

1 reference

14 August 2017

Diabetes and Metabolism

1 reference

14 August 2017

32

1 reference

14 August 2017

1

1 reference

14 August 2017

7-13

1 reference

Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study.

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Hyperglycemia and microvascular and macrovascular disease in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

An analysis of excess mortality rates for persons with non-insulin-dependent diabetes mellitus in Western Australia using the Cox proportional hazards regression model

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Standards of medical care in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Racial and ethnic differences in glycemic control of adults with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Hypoglycemia is the limiting factor in the management of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Timely addition of insulin to oral therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Combination therapies with insulin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

1 reference

7 January 2021

Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Insulins today and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Global assessment for quality and safety of control in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Should seven be the magic number of type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Injection-meal interval: recommendations of diabetologists and how patients handle it.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Insulin Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Effects of Rapid-Acting Insulin Analogs on Overall Glycemic Control in Type 1 and Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycemia. An observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970241-0

7 January 2021

10.1016/S1262-3636(07)70241-0

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16523182